Versanis Bio
Kiran Dole has served as Vice President and Head of Clinical Operations since June 2021. Kiran has close to 20 years of drug development experience across a broad array of therapeutic areas and industry settings. Prior to joining Versanis, Kiran lead the ClinOps group at Gelesis Inc., established the groundwork for conducting clinical trials in the novel space of digital therapeutics at Pear Therapeutics and assisted with the expansion of the ClinOps group at Forma Therapeutics. The bulk of Kiran’s drug training comes from Novartis where she worked on early phase clinical trials, ranging from first in human to proof of concept.
Kiran graduated with a doctorate in Pharmacy from SUNY Buffalo and a Bachelor of Science in Biochemistry from the University of Toronto.
This person is not in any offices
Versanis Bio
Versanis Bio is to discover and develop first-in-class medicines that address medical conditions prevalent in older adults.